Activated KRAS signaling is associated with multiple cancer types [22-25], including colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). This evidence concerns the gene KRAS and non-small cell lung carcinoma.